Phase 4 Alzheimer's Disease Trial, Recruiting NCT05908695 Sponsor: Green Valley (Shanghai) Pharmaceuticals Co., Ltd. Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 4 Alzheimer's Disease Trial, Recruiting

NCT05908695
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People diagnosed with mild to moderate Alzheimer's disease, as defined by NIA-AA guidelines.
  • People who have shown a gradual decline in memory and daily functioning over at least one year.
  • People whose score on the MMSE memory test falls between 11 and 24 out of 30 at the start of the trial.
  • People whose score on the Hachinski Ischemic Scale (a test related to blood flow in the brain) is 4 or lower.
  • People whose score on the Hamilton Depression Rating Scale (a measure of depression symptoms) is 10 or lower.
  • People whose brain MRI scan results point most strongly toward Alzheimer's disease as the diagnosis.
  • People who have a reliable family member, friend, or carer who can participate in the study with them.
  • People willing to sign a form giving their informed consent to take part.

Who may not be able to join:

  • People diagnosed with a brain or nervous system condition that causes dementia, other than Alzheimer's disease.
  • People whose MRI scan shows a significant structural problem in the brain.
  • People whose resting heart rate is below 50 beats per minute after resting for 10 minutes.
  • People who have had a serious or unstable medical condition in the 12 months before screening.
  • People who have taken donepezil, rivastigmine, galanthamine, huperzine A, memantine, or aducanumab within the 6 months before the trial starts.
  • People whose liver is not functioning at an adequate level.
  • People whose other major organs are not functioning at an adequate level (confirm with trial site).
  • People whose ECG (heart electrical activity test) shows clinically significant abnormalities.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +86 21 50504988

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Registry
ClinicalTrials.gov
Start date
31 August 2023
Est. completion
1 June 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change from baseline in the ADAS-cog/12 score; Change from baseline in ADCS-ADL23 score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov